Indivior PLC (LON:INDV - Get Free Report)'s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,020.41 ($13.28) and traded as low as GBX 773.50 ($10.07). Indivior shares last traded at GBX 789.50 ($10.28), with a volume of 693,400 shares traded.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 1,500 ($19.53) target price on shares of Indivior in a research note on Thursday, September 5th.
Read Our Latest Research Report on Indivior
Indivior Stock Down 0.3 %
The firm's 50-day simple moving average is GBX 725.74 and its 200-day simple moving average is GBX 1,020.41. The company has a market capitalization of £1.02 billion, a price-to-earnings ratio of -986.88, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.85.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.